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Background: Robot-assisted radical prostatectomy (RARP) has been rapidly adopted without robust evidence comparing its
functional outcomes against laparoscopic radical prostatectomy (LRP) or open retropubic radical prostatectomy (ORP)
approaches. This study compared patient-reported functional outcomes following RARP, LRP or ORP.
Methods: All men diagnosed with prostate cancer in England during April – October 2014 who underwent radical prostatectomy
were identified from the National Prostate Cancer Audit and mailed a questionnaire 18 months after diagnosis. Group differences
in patient-reported sexual, urinary, bowel and hormonal function (EPIC-26 domain scores) and generic health-related quality of life
(HRQoL; EQ-5D-5L scores), with adjustment for patient and tumour characteristics, were estimated using linear regression.
Results: In all, 2219 men (77.0%) responded; 1310 (59.0%) had RARP, 487 (21.9%) LRP and 422 (19.0%) ORP. RARP was associated
with slightly higher adjusted mean EPIC-26 sexual function scores compared with LRP (3  5 point difference; 95% CI: 1.1–5.9,
P¼ 0.004) or ORP (4.0 point difference; 95% CI: 1.5–6.5, P¼ 0.002), which did not meet the threshold for a minimal clinically
important difference (10–12 points). There were no significant differences in other EPIC-26 domain scores or HRQoL.
Conclusions: It is unlikely that the rapid adoption of RARP in the English NHS has produced substantial improvements in
functional outcomes for patients.
Radical prostatectomy (RP) is a primary treatment option for men
with localised prostate cancer (PCa) (Anandadas et al, 2011;
Eggener et al, 2011; Donovan et al, 2016). Robot-assisted radical
prostatectomy (RARP) has been rapidly adopted despite the lack of
evidence demonstrating superior oncological or functional
outcomes compared with laparoscopic (LRP) or open retropubic
radical prostatectomy (ORP).
Various studies have compared sexual and urinary function and
health-related quality of life (HRQoL) according to RP type
(Ficarra et al, 2012a, b; Yaxley et al, 2016; Herlemann et al, 2017).
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However, many of these studies recruited patients from a single
surgeon, single institution, or from tertiary medical centres. One
community-based and two population-based studies from the USA
and one multi-centre study from Sweden compared functional
outcomes (Barry et al, 2012; Haglind et al, 2015; O’Neil et al, 2016;
Herlemann et al, 2017). However, one of these studies used a
predominantly historical control group (patients enrolled in 1994–
1995; O’Neil et al, 2016) and none used fully validated measures of
urinary continence and erectile function (Barry et al, 2012; Haglind
et al, 2015; O’Neil et al, 2016; Herlemann et al, 2017).
The National Prostate Cancer Audit (NPCA) collects the data
prospectively on the diagnosis, management and outcomes of every
newly diagnosed man with PCa from all providers of PCa services
in the National Health Service (NHS) in England and Wales. The
patient-reported outcomes collected by the NPCA provide
important and unique evidence. First, it is a national study that
includes a truly representative sample – all patients in all surgical
centres in the English NHS are invited to participate. Second, it is
the only population-based study that uses the same validated
instruments throughout the study to capture outcomes for patients
who had radical treatment. Third, all participating patients were
diagnosed in 2014, providing contemporary results. We used this
evidence to compare the functional outcomes after RARP, LRP or
ORP reported by patients 18 months after diagnosis.
MATERIALS AND METHODS
Study design and participants. All patients diagnosed with PCa
in England between 1 April 2014 and 30 September 2014 as
recorded in the NPCA database and who subsequently underwent
RP were eligible for inclusion (ICD-10 and OPCS-4). This database
includes relevant data items from the English National Cancer
Registration and Analysis Service (www.ncras.nhs.uk) and the data
items specific to the NPCA (The National Prostate Cancer Audit,
2016a).
This study was exempt from NHS Research Ethics Committee
approval because it involved analysis of pseudonymised linked data
collected for the purpose of service evaluation as part of the
National Clinical Audit and Patient Outcomes Programme.
Survey design, administration and data handling. The NPCA
patient questionnaire was designed to determine patients’ views of
their functional outcomes and their HRQoL following radical
treatment. The questionnaire includes the EPIC-26, a validated
instrument comprising 26 items to measure patient function and
bother in five domains (urinary incontinence; urinary irritation/
obstruction; bowel function; sexual function; hormonal distur-
bance). Each domain has 4–7 items. The validated summary score
for each domain ranges from 0 to 100 with higher scores
representing better function (Szymanski et al, 2010). Thresholds
for a minimal clinically important difference (MCID) have been
estimated for each EPIC-26 domain, representing changes
considered to be meaningful for patients (Skolarus et al, 2015).
The EuroQol (EQ-5D-5L) describes generic HRQoL based on
five domains (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression) with responses at five levels (‘no
problems’, ‘slight problems’, ‘moderate problems’, ‘severe pro-
blems’, and ‘unable to/extreme problems’). An index score,
expressed on a scale with 0 representing ’death’ and 1 ’perfect
health’, is calculated by matching the pattern of the five responses
against a set of utilities derived from the general UK population
(Herdman et al, 2011).
Questionnaires were mailed to the homes of all identified men
18 months after they were diagnosed. Two reminders were sent to
non-responders 3 and 6 weeks after the first mail out.
The survey response data were linked to records from the NPCA
prospective audit database and Hospital Episodes Statistics (HES),
an administrative database of all admissions to the English NHS
(http://content.digital.nhs.uk/hes). The ICD-10 system classifies
diseases and other health conditions and the OPCS-4 classifies
interventions and surgical procedures (ICD-10 and OPCS-4).
The survey questionnaire provided the data on ethnicity and
comorbidities. The NPCA database was the data source for age at
diagnosis, tumour characteristics according to TNM scores,
Gleason biopsy score, serum PSA and asdditional treatments
(adjuvant/salvage external beam radiotherapy and androgen
deprivation therapy [ADT]). Hospital Episodes Statistics was used
to determine socioeconomic deprivation and type of RP (OPCS-4
Classification of Diseases codes for RARP: Y753, Y765; ORP: Y508,
Y751, Y752, Y763, Y768).
Socioeconomic deprivation was measured with the Index of
Multiple Deprivation (IMD) for lower super output areas (small
geographic areas with population of B1500 people) (Noble et al,
2008). Areas were grouped into five categories according to
national quintiles of the IMD ranking with higher scores indicating
more deprivation.
Men were classified as having low-risk localised, intermediate-
risk localised, locally advanced or advanced cancer based on their
TNM stage, Gleason score, and PSA level, according to a
previously developed algorithm (The National Prostate Cancer
Audit, 2016b).
Outcomes. Primary outcome measures were the five EPIC-26
domain scores and the EQ-5D-5L index score according to RP
technique. Missing patient response data to individual questions
were handled in accordance with respective guidelines for EPIC-26
and EQ-5D-5L (The University of Michigan, 2002; The EuroQoL
Group, 2015).
Statistical analysis. We used multivariable linear regression to
estimate differences in outcomes with adjustment for patient
characteristics, including age, patient-reported number of comor-
bidities and ethnicity, cancer risk group according to NPCA data
(determined on the basis of TNM stage, Gleason score and PSA
level), and socioeconomic status according to HES. All P-values
were based on the Wald test.
Multiple imputation by chained equations accounted for
missing values of the adjustment variables and outcomes so that
regression models included all 2219 patients (White et al, 2011).
Missing values were replaced with 50 sets of plausible values and
Rubin’s rules were used to combine estimates and obtain adjusted
differences with 95% confidence intervals (95% CI).
All reported P-values are two-sided and Po0.05 was considered
statistically significant without adjustment for multiple compar-
isons. Adjusted differences in EPIC-26 domain scores were
considered to be clinically relevant if the differences reached the
threshold for a MCID (Skolarus et al, 2015). The data analysis was
undertaken using Stata version 14 (StataCorp. 2015. Stata
Statistical Software (College Station, TX, USA).
RESULTS
Response rate and data completeness. Of the 2883 eligible men
who underwent RP at all prostatectomy centres (n¼ 55) in
England and received a questionnaire, 2219 (77.0%) responded.
Compared with non-responders, responders tended to be older,
were more commonly of white ethnicity, reported fewer comor-
bidities, and were less likely to live in more socioeconomically
deprived areas (Supplementary Table 1). The missing data levels
were low, typically o5% for the majority of fields in the
questionnaire.
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Patient characteristics. Of the 2219 responders, 1310 (59.0%) had
RARP, 487 (21.9%) LRP, and 422 (19.0%) ORP. Most responders,
1954 men (91.4%), underwent surgery within 6 months from
diagnosis and 1714 men (80.1%) completed the surveys 12–18
months from surgery. There was no evidence that timing of
surgery was related to RP type.
Patient characteristics are presented in Table 1. The majority of
men were p70 years (89.2%) and of white ethnicity (93.9%).
Overall, men from more socio-economically deprived backgrounds
were under-represented . About one-third of men reported no
comorbidities. In all, 7.6% of men also received radiotherapy and
4.6% ADT. There were only small differences in patient
characteristics across RP group. For example, men who underwent
ORP tended to be slightly older, and more often of white ethnicity.
Men who underwent LRP were less likely to be in the most socio-
economically deprived national quintile.
Tumour characteristics. Tumour characteristics were very similar
across surgical groups (Table 2). Overall, 59.6% of men had
tumour stage T2 and 38.2% stage T3/T4. However, men having
ORP slightly more often had positive nodal stage N1, a Gleason
score X8, and PSA levels X10. Consequently, the cancer risk
profiles for men undergoing RARP or LRP were similar, but
slightly more men undergoing ORP had locally advanced or
advanced disease.
Patient-reported outcomes according to RP type. Robot-assisted
radical prostatectomy was associated with slightly higher adjusted
mean EPIC-26 sexual function scores (Table 3) compared with
LRP (adjusted mean difference 3  5 points; 95% CI: 1.1–5.9,
P¼ 0.004) or ORP (adjusted mean difference 4  0 points; 95% CI:
1.5–6.5, P¼ 0.002). These differences were smaller than the
established threshold for a MCID of 10–12 points (Skolarus
et al, 2015).
There was no significant difference in EPIC-26 urinary
incontinence, urinary irritation, bowel and hormonal function
scores or EQ5D-5L index scores between RARP and LRP or ORP
(Table 3).
DISCUSSION
In this contemporary, observational study of all men diagnosed
with PCa in the English NHS between 01 April 2014 and 31
October 2014 who underwent RP in prostatectomy centres
nationwide, RARP was associated with better sexual function than
LRP or ORP, 18 months after diagnosis. However, the difference in
EPIC-26 sexual function scores (3.5 point difference for RARP
compared with LRP and 4 point difference for RARP compared
with ORP on a scale ranging from 0 to 100) is considerably smaller
than the established threshold for a clinically meaningful change
(10–12 points) (Skolarus et al, 2015). This suggests that most
patients would not identify this difference in sexual function as
important. There was no significant difference in other measured
functional parameters, including continence or HRQoL.
Our results concur with a recent phase 3 randomised controlled
trial (RCT) comparing 163 men undergoing RARP with 163 men
having ORP (Yaxley et al, 2016). This, to our knowledge, the
largest RCT to date, found no significant differences in the EPIC
sexual and urinary function scores 12 weeks after surgery.
However, this RCT included a young cohort of patients (mean
Table 1. Patient characteristics by type of radical
prostatectomy
RARP n (%) LRP n (%) ORP n (%) Total n (%)
No. of patients 1310 (59.0%) 487 (21.9%) 422 (19.0%) 2,219
Age at diagnosis
(years)
p60 368 (29.2%) 121 (25.9%) 88 (22.0%) 577 (27.1%)
61–70 780 (61.9%) 284 (60.7%) 256 (63.8%) 1320 (62.1%)
470 111 (8.8%) 62 (13.2%) 57 (14.2%) 230 (10.8%)
Missing 51 20 21 92
Ethnicity
White 1180 (92.5%) 453 (94.0%) 399 (97.6%) 2,032 (93.9%)
Non-white 94 (7.8%) 28 (5.8%) 10 (2.4%) 132 (6.1%)
Missing 36 6 13 55
Socioeconomic
deprivation
Least deprived
quintile
339 (26.3%) 131 (27.0%) 119 (28.2%) 589 (26.8%)
2nd 311 (24.1%) 122 (25.2%) 99 (23.5%) 532 (24.2%)
3rd 292 (22.%) 117 (24.3%) 87 (20.6%) 496 (22.6%)
4th 186 (14.5%) 78 (16.1%) 57 (13.5%) 321 (14.7%)
Most deprived
quintile
161 (12.5%) 36 (7.4%) 60 (14.2%) 257 (11.7%)
Missing 21 3 0 24
Comorbidities
0 465 (35.5%) 149 (30.7%) 136 (32.2%) 750 (33.8%)
X1 845 (64.5%) 338 (69.3%) 286 (67.8%) 1469 (66.2%)
Additional
treatments
Radiotherapy
(EBRT)
97 (7.4%) 35 (7.2%) 38 (9.0%) 170 (7.6%)
Androgen
deprivation
51 (3.9%) 22 (4.5%) 28 (2.8%) 101 (4.6%)
Abbreviations: LRP¼ laparoscopic radical prostatectomy; ORP¼open retropubic radical
prostatectomy; RARP¼ robot-assisted radical prostatectomy.
Table 2. Tumour characteristics by type of radical
prostatectomy
RARP n (%) LRP n (%) ORP n (%) Total n (%)
No. of patients 1310 (59.0%) 487 (21.9%) 422 (19.0%) 2 219
Tumour stage
T stage
T1 28 (2.4%) 10 (2.3%) 8 (2.0%) 46 (2.3%)
T2 713 (60.3%) 256 (58.5%) 236 (58.7%) 1205 (59.6%)
T3/T4a 441 (37.2%) 173 (39.3%) 158 (39%) 772 (38.2%)
Missing 128 48 20 196
N stage
N0 1057 (96.7%) 389 (98.2%) 370 (94.9%) 1816 (96.5%)
N1 36 (3.3%) 7 (1.8%) 19 (4.9%) 62 (3.3%)
Missing 217 91 33 341
Gleason score
p6 217 (20.6%) 108 (24.9%) 68 (19.0%) 393 (21.3%)
7 708 (67.2%) 283 (65.3%) 224 (62.6%) 1215 (65.8%)
X8 129 (12.2%) 43 (9.9%) 66 (18.4%) 238 (12.9%)
Missing 256 53 64 373
PSA (ng/ml 1)
o10 664 (66.9%) 296 (72.4%) 212 (60.1%) 1172 (66.8%)
10–20 264 (26.6%) 97 (23.7%) 115 (32.6%) 476 (27.1%)
420 65 (6.6%) 16 (3.9%) 26 (7.4%) 107 (6.1%)
Missing 317 78 69 464
Cancer risk profile
Low/
intermediateb
547 (50.8%) 220 (51.9%) 172 (45.7%) 939 (50.0%)
Locally
advanced/
advanced
530 (49.2%) 204 (48.1%) 204 (54.3%) 938 (50.0%)
Insufficient
informationc
233 63 46 342
Abbreviations: LRP¼ laparoscopic radical prostatectomy; ORP¼open retropubic radical
prostatectomy; RARP¼ robot-assisted radical prostatectomy.
aOverall, there were 6 patients with T4.
bOverall, there were 15 patients with a low risk cancer.
cOverall, there were 4 patients with advanced cancer.
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age, 60 years), compared two high-volume surgeons and used the
EPIC-50 instrument rather than the EPIC-26, and these differences
in study design are likely to explain the lower sexual function
scores reported in our observational study. Previous smaller RCTs
reported that patients having RARP had significantly better sexual
function one year after surgery (Asimakopoulos et al, 2011) and
had improved recovery of both urinary and sexual function
(Porpiglia et al, 2013). This is in agreement with the results of
previous systematic reviews comparing RARP with other RP types,
including studies with a range of different designs (Ficarra et al,
2012a).
Other population-based or multi-centre studies demonstrated
no or at best modest improvements in functional outcomes with
RARP. However, these studies are limited by the use of non-
standard instruments or single items to capture sexual or urinary
function and inclusion of selected populations (Barry et al, 2012;
Haglind et al, 2015; Gershman et al, 2016; O’Neil et al, 2016;
Herlemann et al, 2017).
Three studies in the USA compared RARP and ORP. The first
of these studies included patients from a claims-based database and
found that patients reported a moderate or big problem with
urinary continence following RARP but there was no difference in
sexual function (Barry et al, 2012). The second study compared
men having RARP in 2011 and 2012, with a historical comparison
group who underwent ORP predominantly in 1994 and 1995, and
found no significant difference in 12-month urinary function and a
modest increase in sexual function with RARP (O’Neil et al, 2016).
The third study included men who had a RP around 2011 and
demonstrated higher, unadjusted 12-month urinary incontinence
scores for RARP with no difference in functioning after this time
(Herlemann et al, 2017).
A study comparing patients having RARP, LRP, and ORP
performed by high-volume surgeons (425 procedures per year) in
two centres in the USA found no evidence that sexual or urinary
functional outcomes were linked to type of surgery (Gershman
et al, 2016). It is important to note that European, population-
based studies are lacking. One study in Sweden including 14
centres found slightly better 12-month sexual function in patients
having RARP compared with ORP but little difference in urinary
function (Haglind et al, 2015).
A strength of our study is that it reports results from a
contemporary national cohort study that collected data prospec-
tively on all men newly diagnosed with PCa in the English NHS in
2014. Further strengths include a robust sample size, a high
response rate to the survey (77.0%), the collection of patient
reported functional outcomes at a fixed time period after diagnosis,
and the use of the same validated instruments to determine
disease-specific function and HRQoL from all patients.
Our study is subject to confounding by clinical indication.
However, the observed patient and tumour characteristics were
very similar across prostatectomy type, which reduces the potential
impact of confounding. There were small differences that may have
a favourable impact on patients who had RARP, given that these
men were slightly younger with less comorbidities. Conversely,
patients who underwent ORP more often had locally advance/
advanced disease (nodal positivity, a Gleason score X8, or PSA
level of X10), which may have a less favourable impact on these
patients. We adjusted for age, comorbidity, ethnicity, socio-
economic background, and cancer risk profile in the analyses,
but these characteristics had very little impact on the difference
between the RP groups. Furthermore, the choice of type of surgery
depended strongly on where a patient had his treatment rather
than on his specific characteristics because most hospitals offer
only one surgical technique at a given time (NPCA unpublished
data). This further reduces the likelihood of patients being
allocated to one treatment or another based on their individual
risk characteristics at diagnosis. Data on lymph node dissection
were unavailable in this study.
Similar to previous studies undertaken in England that
presented patient-reported outcomes, non-responders were
younger, more often non-white, and lived in less affluent areas
(Hutchings et al, 2012). However, the response rate did not vary
according to type of prostatectomy, suggesting that the impact of
non-response on the observed difference is likely to be very small.
As men were surveyed 18 months after diagnosis, the time from
surgery to completion varied. However, the majority of men
Table 3. Relationship between patient-reported outcomes post-procedure and type of radical prostatectomy (ORP, LRP and
RALP): overall domain scores for EPIC-26 and EQ5D-5L and adjusted differences for RARP vs LRP and RARP vs ORP
RARP LRP ORP
RARP vs LRP Adjusted difference
(95% CI)
RARP vs ORP Adjusted difference
(95% CI)
No. of patients 1310 (59.0%) 487 (21.9%) 422 (19.0%)
EPIC-26
Urinary (incont.)
Mean (SD) 70.5 (28.0) 68.5 (29.5) 70.1 (27.3) 1.2 ( 1.7,4.2) P¼0.4 0.3 (3.1, 3.1) P¼ 0.9
Missing 70 28 31
Urinary (irrit./
obst.)
Mean (SD) 91.4 (11.8) 91.2 (11.7) 91.0 (11.7) 0.18 (1.8, 1.5) P¼ 0.8 1.02 (0.70, 2.7) P¼ 0.2
Missing 183 70 78
Sexual
Mean (SD) 24.4 (24.7) 20.1 (22.3) 18.6 (20.5) 3.5 (1.1, 5.9) P¼ 0.004 4.0 (1.5,6.5) P¼0.002
Missing 33 7 14
Bowel
Mean (SD) 94.2 (11.9) 93.8 (11.7) 94.2 (12.7) 0.30 (1.1, 1.7) P¼ 0.7 0.37 (1.9, 1.1) P¼ 0.6
Missing 90 38 42
Hormonal
Mean (SD) 86.8 (16.3) 8.6 (16.3) 86.4 (18.2) 0.32 (2.1, 1.5) P¼ 0.7 0.75 (1.2, 2.7) P¼ 0.4
Missing 72 29 42
EQ-5D
Mean (SD) 0.90 (0.14) 0.89 (0.15) 0.89 (0.16) 0.00( 0.01, 0.02) P¼0.66  0.01( 0.01, 0.02) P¼0.2
Missing 16 7 12
Abbreviations: LRP¼ laparoscopic radical prostatectomy; ORP¼open retropubic radical prostatectomy; RARP¼ robot-assisted radical prostatectomy.
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completed the survey 12–18 months after surgery and there was no
evidence that timing of surgery was related to RP type.
We were unable to administer the questionnaire at the time of
diagnosis, making it impossible to adjust for potential baseline
differences in patient function, bother and generic HRQoL.
However, we included one question in our 18-month questionnaire
asking men ’How would you rate your ability to have an erection at
the time of diagnosis?’ . The proportion of men who indicated that
this was ’very poor/none’ did not vary according to the type of
prostatectomy (reported by 19.4% of men who underwent RARP,
20.3% who had LRP, and 20.7% who had ORP), which further
supports the validity of our comparison.
Finally, this study was carried out at a time when RARP use was
growing rapidly in the English NHS. In 2010, 12 of the 65
prostatectomy centres (19%) provided RARP, but by 2017, this had
changed to 42 of the remaining 49 centres (86%) (Aggarwal et al,
2017). A ’learning curve’ may therefore have had an impact on the
results. The ongoing collection of patient-reported outcomes after
radical treatment for PCa in the NHS will potentially demonstrate
to what extent outcomes with RARP will further improve.
Robot-assisted radical prostatectomy has been rapidly adopted
in many countries and has become the most common type of RP
within the English NHS (The National Prostate Cancer Audit,
2016b; Aggarwal et al, 2017; Sujenthiran et al, 2017). Its use was
partly informed by a large economic evaluation that found that
RARP had a lower rate of positive surgical margins (18%) than
LRP (24%), in addition to lower blood loss and shorter length of
hospital stay although no differences in functional outcomes were
reported (Ramsay et al, 2012). The first phase 3 RCT comparing
RARP and ORP reported no difference in surgical margin status
(Yaxley et al, 2016).
The results of our study, with its lack of clinically relevant
differences in functional outcomes and in generic HRQoL among
patients who had RARP, LRP, or ORP, do not support the
dramatic shift to RARP, which has taken place in the English NHS
and worldwide. These findings have wider implications for the
English NHS when considering the adoption of new technology.
Patient reported outcome measures provide important information
enabling the comparison of treatments and providers, and support
decision making by patients.
CONCLUSIONS
While RARP was associated with marginally better sexual function
scores than LRP or ORP as reported by men 18 months after
diagnosis, this difference is small and unlikely to be clinically
significant. Our study includes a representative sample, as all men
who had a RP in 2014 in each of the surgical centres in the English
NHS were invited to participate. Our results demonstrate that the
rapid adoption of RARP in the English NHS is unlikely to lead to
substantial improvements in functional outcomes for patients.
Continued monitoring of patient-reported outcomes is required to
explore if the benefits of RARP will emerge in the future after
urologists have gained further experience with this type of surgery.
The expertise and skill of an individual surgeon, and comparative
performance of a surgical centre should drive treatment decisions.
Rather than surgical modality alone, robust provider-level functional
outcome measures are needed to support decision making by patients.
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